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Summary
Objective: Cartilage oligomeric matrix protein (COMP) is a large disulfide-linked pentameric protein. Each of its five
subunits is approximately 100,000 Da in molecular weight. COMP was originally identified and characterized in
cartilage and it has been considered a marker of cartilage metabolism because it is currently thought not to be present
in other joint tissues, except for tendon. To confirm the tissue specificity of COMP expression we examined cultured
human dermal fibroblasts, human foreskin fibroblasts, and normal human synovial cells for the synthesis of COMP
in culture.
Method: Normal synovial cells and normal human dermal foreskin fibroblasts were isolated from the corresponding
tissues by sequential enzymatic digestions and cultured in media containing 10% fetal bovine serum until confluent.
During the final 24 h of culture, the cells were labeled with 35S-methionine and 35S-cysteine in serum- and
cysteine/methionine-free medium. The newly synthesized COMP molecules were immunoprecipitated from the culture
media with a COMP-specific polyclonal antiserum, or with monoclonal antibodies or affinity-purified COMP
antibodies. The immunoprecipitated COMP was analyzed by electrophoresis in 5.5% polyacrylamide gels. For other
experiments, synovial cells cultured from the synovium of patients with rheumatoid arthritis(RA) and
osteoarthritis(OA) were similarly examined.
Results: A comparison of the amounts of COMP produced by each cell type (corrected for the DNA content) revealed
that synovial cells produced r 9 times more COMP than chondrocytes or dermal fibroblasts. COMP could be easily
detected by immunoprecipitation in all cell types. Electrophoretic analysis revealed a distinct band with an apparent
MW of 115–120 kDa in samples from each of the three cell types, regardless of the antibody used. COMP expression
in cultures of synoviocytes derived from OA and RA patients showed that OA and RA synovial cells produced similar
amounts of monomeric COMP of identical size to those COMP monomers produced by normal synovial cells. The
addition of TGF-b to these cultures resulted in an increase in COMP production in normal, OA and RA synovial cells
(45, 116 and 115% respectively).
Conclusion: These studies demonstrate that substantial amounts of COMP are produced by several mesenchymal
cells including synoviocytes and dermal fibroblasts. These findings raise important concerns regarding the utility of
measurements of COMP levels in serum or in synovial fluid as markers of articular cartilage degradation because of
the likelihood that a substantial proportion of COMP or COMP fragments present in serum or synovial fluid may be
produced by cells other than articular chondrocytes.
Introduction
Loss of articular cartilage matrix is the hallmark
of degenerative and inflammatory arthritis [1].
Recent interest has been focused on the identifi-
cation of biochemical markers that would accu-
rately follow the process of articular cartilage loss
[2–6]. Cartilage oligomeric matrix protein (COMP)
is a large disulfide-linked pentameric glycoprotein
which was first identified as a structural com-
ponent of articular cartilage extracellular matrix
by Heinegard et al. [7, 8]. Although substantial
knowledge has been recently acquired about its
molecular characteristics, its precise function
within articular cartilage matrix is still unknown.
The COMP molecule is comprised of five disulfide
bonded subunits of 0 100 000 Daltons in molecular
weight [8, 9]. COMP has been shown to be
expressed by chondrocytes from individuals of
various ages, although temporal and spatial
differences have been observed, particularly
during development [10]. With the exception of
cartilage [7, 8], and tendon [11], COMP has not
been identified as a constitutive component of the
extracellular matrix of other tissues. Based on
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these observations it has been suggested that
COMP measurements in serum or in synovial fluid
may serve as a valid indicator of articular cartilage
degradation [2, 4, 12]. The utilization of COMP as
a reliable marker of articular cartilage breakdown
requires that its expression be either confined to
this tissue or, alternatively, that a clear under-
standing of other cells and tissues capable of its
production is available. To confirm the tissue
specificity of COMP expression, we examined
whether COMP synthesis can be detected in
non-chondrocytic cells such as cultured human
dermal fibroblasts and normal human synovial
cells. For these studies, the cells were isolated from
the corresponding tissues by sequential enzymatic
digestions and cultured in media containing 10%
fetal bovine serum until confluent. During the final
24 h of culture, the cells were labeled with
35S-methionine and 35S-cysteine in serum-free and
cysteine/methionine-free medium. Immunoprecipi-
tation of media employing three different COMP-
specific antibodies showed that the three types of
cells produced relatively large amounts of COMP.
A comparison of the amounts produced by each
cell type, corrected for the DNA content of the
cultures, revealed that synovial cells produced r 9
times more COMP than chondrocytes or dermal
fibroblasts. Electrophoretic analysis revealed a
distinct band with an apparent MW of 115–120 kDa
in samples from the three cell types, regardless of
the antibody used. These results were similar to
those obtained with COMP from culture media of
articular chondrocytes from other species [7, 8].
The unexpected demonstration of COMP pro-
duction by synovial cells prompted the investi-
gation of whether there were differences in COMP
expression in cultured synoviocytes from osteoar-
thritis (OA) and rheumatoid arthritis (RA)
patients. The results of these studies showed that
OA and RA synovial cells produced COMP
polypeptides of identical size to those produced by
normal synovial cells. However, there were no
significant differences in the amounts of COMP
produced in unstimulated cultures of the three
types of synovial cells tested (N = 8). When the
effects of TGF-b on the expression of COMP in
synovial cells were examined it was found that
TGF-b caused an increase in COMP production in
normal, OA and RA synovial cells (45, 116 and
115% respectively).
The studies described here demonstrate that
COMP is produced by various mesenchymal cells,
including synoviocytes and dermal fibroblasts.
These findings raise important concerns regarding
the utility of measurements of COMP levels in
serum or in synovial fluid as markers of cartilage
degradation because of the likelihood that a
substantial proportion of COMP or COMP frag-
ments present in serum or synovial fluid may be
produced by cells other than articular chondro-
cytes and, particularly, by cells from synovium, a
tissue critically involved in joint diseases. Further
characterization of the expression and regulation
COMP in synovium and dermis will help to
elucidate the role of this homopolymeric matrix
molecule in tissue homeostasis and inflammatory
connective tissue diseases.
Methods
Isolation and culture of cells
Normal articular cartilage was obtained from
the knees from healthy adults through the organ
donor network (NDRI, Philadelphia, PA). Chon-
drocytes were isolated from the tibial plateau and
femoral chondyles of samples procured less than
18 h post-mortem, employing sequential enzymatic
digestions (trypsin/collagenase, Worthington Bio-
chemicals, Freehold, NJ) as described [13]. Single
cell suspensions of isolated chondrocytes were
washed three times in Dulbecco’s modified Eagle’s
medium (DMEM), counted, and cultured in
suspension at a density of 5–10 · 106 chondrocytes/
60 mm dish. The culture dishes were pre-coated
with poly–(2–hydroxyethyl methacrylate (poly-
HEMA) as described [13]. Chondrocyte cultures
were routinely maintained in DMEM sup-
plemented with 10% fetal bovine serum (Whit-
taker, Walkersfield, MD) containing 1% vitamin
solution (GIBCO, Gaithersburg, MD), 2 mM L-glu-
tamine, 100 units/ml penicillin, 100 mg/ml strepto-
mycin, 2.5 mg/ml amphotericin B (Boehringer
Mannheim, Indianapolis, IN) and 50 mg/ml
ascorbic acid. We have previously shown that
under these culture conditions the chondrocytes
maintain a cartilage-specific phenotype for at least
8 months [13]. For metabolic labeling and
subsequent immunoprecipitation the cells were
cultured in serum-free and methionine/cysteine-
free medium.
Synovial cells from normal, OA, and RA
synovium were established employing an explant
outgrowth technique where explants of synovial
tissue are grown in cultures until synovial
fibroblasts migrate out and can be propagated. The
synovial tissues were removed at the time of
arthroplasty or amputation. Cells were stored in
the TJU/Rheumatology Division’s Tissue/Cell
Bank under cryogenic conditions and were used at
a passage r 4. Normal human foreskin fibroblasts
(ATCC ( 2208) and synovial fibroblasts were
Osteoarthritis and Cartilage Vol. 6 No. 6 437
cultured in minimum essential medium (MEM)
(Mediatech, Herndon, VA) supplemented as de-
scribed above for DMEM. In experiments in which
the effects of TGF-b on COMP production were
examined, cultures of either chondrocytes or
synovial cells were treated for the last 24 h with
5 ng/ml recombinant human TGF-b (Boehringer
Mannheim).
Metabolic labeling and immunoprecipitation
To perform a quantitative comparison of the
amounts of COMP synthesized by dermal and
synovial fibroblasts with that synthesized by
chondrocytes, each culture was washed twice with
10 ml DMEM to remove the serum and then with
methionine/cysteine-free-DMEM containing 0.1%
bovine serum albumin. 35S-labeled cysteine and
methionine (Expre35S35S, Amersham, Arlington
Heights, IL) was added to the cultures for the last
24 h. Following metabolic labeling, the media were
removed and stored, and the cell layers (for DNA
assay) were harvested in cold PBS containing 1%
Nonidet, 0.5% sodium deoxycholate and 0.1% SDS.
An aliquot of a proteinase inhibitor mixture
(Complete, Boehringer Mannheim) was added to
the medium and cell layer lysate from each sample
prior to freezing. The immunoprecipitation was
performed using three different antibodies: LS25,
which is a polyclonal antiserum (raised against
human COMP from cultures of ligament cells) that
reacts with COMP monomers [14]; 6F/12A which is
a pool of two monoclonal antibodies which were
raised against purified human COMP (generously
provided by D. Heinegard); and DH, an affinity-
purified polyclonal anti-human COMP antibody
(generously provided by D. Heinegard). For these
experiments, 100 ml of medium or cell layer lysate
samples were mixed with 150 ml PBS containing 1%
Triton X-100, 0.5% sodium deoxycholate, 2 mg/ml
BSA, and the protease inhibitors described above.
Each sample was pre-incubated with normal rabbit
IgG (when polyclonal antibodies were employed
for immunoprecipitation) or mouse IgG (when
monoclonal antibodies were used) and sub-
sequently with an affinity purified polyclonal
antiserum to fibronectin (Cappel Organon
Teknika, Durham, NC). The samples were then
precleared by precipitation with 10 ml protein A/G
PLUS-agarose (Santa Cruz Biotechnology, Santa
Cruz, CA) and washed repeatedly as outlined by
the manufacturer. Following the last washing, the
pellets were collected by centrifugation for 5 min
at 12 000 · g and washed once in 100 ml of ethanol
and held at - 80° C for r 15 min. The supernatants
were decanted and the pellets were air-dried and
then resuspended in 20 ml SDS-PAGE sample buffer
containing 1% b-mecaptoethanol (ME) (unless
noted otherwise), heated for 10 min at 100° C and
centrifuged for 5 min. When COMP was evaluated
under non-reducing conditions, the samples were
resuspended in 40 ml of SDS-PAGE sample buffer
without ME and each sample was divided into two
aliquots one of which was subsequently reduced
with 1% ME. A 15 ml aliquot of the supernatants
was loaded onto 5.5% polyacrylamide gels (SDS-
PAGE) and electrophoresed at 100 V for 0 1 h. The
gels were fixed in a solution of 45% methanol and
15% acetic acid, dried, and analyzed using a
PhosphorImaging System (Molecular Dynamics,
Sunnyvale, CA).
Results and Discussion
To determine whether COMP was constitutively
synthesized by fibroblasts and synovial cells,
confluent cultures were metabolically labeled for
24 h and the amounts of COMP produced by each
cell type were compared with the amounts of
COMP produced by human articular chondrocytes.
We have previously shown that under these
culture conditions the chondrocytes maintain a
cartilage-specific phenotype for at least 8 months
[13]. For purposes of comparison, media were
collected from 2–4 day-old primary suspension
cultures of adult human chondrocytes and from
confluent monolayer cultures of fibroblasts and
synovial cells. Immunoprecipitation assays were
performed employing equal concentrations of total
protein (as determined by incorporated 35S-meth-
ionine and cysteine). In the experiment shown in
Figure 1, COMP was precipitated using a
monoclonal antibody (6F/12A) to COMP and
electrophoresed under reducing conditions. Figure
1A shows the COMP monomers detected in
chondrocytes (lane 1), human foreskin fibroblasts
(lane 2), and normal synovial cells (lane 3). The
COMP monomers produced by fibroblasts and
synovial cells examined under reducing conditions
were of identical size ( 0 115 kDa) to COMP
monomers synthesized by human articular chon-
drocytes. To exclude any cross-reactivity with
fibronectin, aliquots of media from chondrocytes,
fibroblasts and synovial cell cultures were pre-
cleared with an affinity-purified antibody to
fibronectin. Several bands corresponding to
fibronectin and related polypeptides were partially
removed by the initial pre-clearing precipitation
(Figure 1A, lanes 4–6). A comparison of the levels
of COMP synthesized by each cell type corrected
for the DNA content of each culture showed that
the relative amount of COMP/ng DNA was r 9
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times higher in synovial cells than in chondrocytes
(Figure 1B). The amounts of COMP synthesized by
foreskin fibroblasts was approximately equal to
that synthesized by human articular chondrocytes.
Although other studies have indicated that
synovial cells produced COMP under stimulation
Fig. 2. Characterization of COMP immunoprecipitated
by three different anti-COMP antibodies and the effects
of disulfide bond reduction on the electrophoretic
mobility of COMP from cultured synovial cells and
chondrocytes. Samples of media from cultures of normal
synovial cells (lanes 1,4,7), synovial cells from RA
synovium (lanes 2,5,8), and normal adult chondrocytes
(lanes 3,6,9), labeled with 35S-methionine/35S-cysteine
were immunoprecipitated and electrophoresed under
non-reducing (A) and reducing conditions (B) as
described in Methods. Lanes 1-3 samples immunoprecip-
itated with LS25 polyclonal antisera [14]. Lanes 4–6
samples immunoprecipitated with affinity purified DH
polyclonal antibodies. Lanes 7–9 samples immunoprecip-
itated with 6F/12A monoclonal antibodies. The position
of migration of pentameric COMP is indicated in panel
A as a doublet of 0 500 kDa and that of COMP
monomers is indicated in panel B at 0 120 kDa. The *:
in panel B indicates the two additional bands recognized
by the 6F/12A anti-COMP antibody that are found to be
present only in samples from normal and RA synovial
cells.
Fig. 1. Comparison of COMP expression in human
dermal and synovial fibroblasts, and normal human
adult articular chondrocytes. Chondrocytes were cul-
tured under conditions that allow the preservation of
their cartilage-specific phenotype [13]. Chondrocytes
and dermal and synovial fibroblasts were labeled with
35S methionine/cysteine as described in Methods. An
aliquot of medium from each cell culture was im-
munoprecipitated and electrophoresed under reducing
conditions as described in Methods. A. Immunoprecipi-
tation of aliquots of culture media from each cell type
containing equal quantities of total protein. Figure 1A
shows the COMP monomers detected using the
monoclonal 6F/12A in chondrocytes (lane 1), human
foreskin fibroblasts (lane 2), and normal synovial cells
(lane 3). The bands immunoprecipitated by preclearing
with fibronectin antibodies are shown in chondrocytes,
fibroblasts and synovial cells (lanes 4, 5, and 6,
respectively). B. Graphic representation of the relative
COMP amounts produced by dermal and synovial
fibroblasts, and by normal adult articular chondrocytes
corrected for the concentration of DNA of each culture.
The data were obtained using a PhosphorImager
(Applied Biosystems) and are expressed as pixel volume
(PV).
with TGF-b [15], our data show conclusively that
COMP was constitutively produced by cultures of
dermal fibroblasts and synovial cells grown in the
absence of serum or exogenous stimuli. In the
number of cultures examined thus far there were
no significant differences in the amounts of COMP
produced in unstimulated cultures of the three
types of synovial cells tested (N = 8). When the
effects of 5 ng/ml of TGF-b on the synthesis of
COMP in normal, OA and RA synovial cells were
studied, it was found that the growth factor caused
a 45, 116 and 115% increase respectively, in COMP
biosynthesis (N = 2) corrected for DNA content and
any differences in media volumes in the three types
of synovial cells analyzed (Figure 3).
The data presented here demonstrate
conclusively that synovial and dermal fibroblasts
constitutively produce substantial levels of COMP
and that the unstimulated COMP production in
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normal human synovial cells is much higher than
in human articular chondrocytes. In addition, it
was shown that COMP biosynthesis can be
stimulated by TGF-b in all the synovial cell
cultures examined. These findings expand the
current understanding of the tissue distribution of
COMP production and raise concerns regarding
the utility of determination of COMP or COMP
fragments in serum or synovial fluids as markers of
cartilage pathology.
To further characterize the newly synthesized
COMP in the three cell types, immunoprecipita-
tion with three different anti-COMP antibodies
followed by gel electrophoretic analysis under
reducing and non-reducing conditions was per-
formed. Figure 2A shows that under non-reducing
conditions, the newly synthesized COMP immuno-
precipitated with the three antibodies migrated as
a doublet with an apparent 0 500 kDa MW (left
arrow). A similar pattern of migration was
observed in samples from normal synovial cells
(lanes 1,4,7), synovial cells from RA synovium
(lanes 2,5,8), and normal adult chondrocytes (lanes
3,6,9), regardless of the antibody used for immuno-
precipitation. When identical samples were exam-
ined following reduction, it was found that COMP
migrated as monomers with an estimated MW of
0 115 kDa and its migration was the same in all
the cell cultures tested (Figure 2B). Two unique
bands were identified using the LS25 polyclonal
antisera in the samples from the synovial cells in
Figure 2B, lanes 1 and 2 (*:). It is not apparent at
this time whether these bands represent some
unique feature of synovial cell COMP or are the
result of cross-reaction of the antibodies with an
unidentified protein(s).
The data presented here demonstrate that
COMP, previously considered to be a cartilage-
specific extracellular matrix molecule [7, 8], is
ubiquitously expressed by cells from various
tissues throughout the body, including mesenchy-
mal cells such as dermal and synovial fibroblasts.
Although these data do not preclude the utiliz-
ation of COMP or COMP fragments as markers of
connective tissue damage occurring in various
forms of arthritis [14], they raise concerns
regarding their specificity as indication of changes
in articular cartilage matrix. In light of these data
COMP fragments may indeed be the result of
active synovitis. However, it is very likely that
COMP found in synovial fluid and blood arises
from a variety of cellular sources in addition to
articular cartilage. Our data would lead us to
suggest that while a non-invasive marker of
cartilage pathology is paramount to early detec-
tion of diseases affecting articular cartilage,
COMP does not fulfill that role.
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